Legislation removes FDA involvement when patients seek experimental medications. Here’s what critics and proponents say.
Two health plans are sharing the wealth—in this case, drug discounts from manufacturers—with consumers at point of sale.
Experts weigh in on the spending outlook for these high-cost conditions.
Gene therapy is leaving its mark, while payers contemplate payment models, value, and efficacy issues.
A lack of national standards and less than optimal oversight of many inpatient, opioid addiction rehabilitation programs is raising questions about the level of services, personnel, and quality of care many patients are receiving.
Find out what challenges top the list, and what analysts say can be done about them.
Prepare for major pipeline developments in diabetes, autoimmune disorders, oncology, and COPD.
PBMs partnering with pharmacies and drug makers may have a solution to nonadherence due to high pharma costs.
Polypharmacy presents real problems—especially for older adults.
Despite front-end scrutiny, payers seek audit process to improve high-cost specialty pharmacies.